CAM Guidance Statement On Probiotics Is “Astonishing,” Concerns Experts
This article was originally published in The Tan Sheet
Executive Summary
FDA's Center for Biologics Evaluation and Research may be laying the groundwork for greater control of the regulation of probiotics in the agency's recently released guidance document on "complementary and alternative medicine products," according to industry stakeholders
You may also be interested in...
Israelsen GMP Tips: Watch “Wild Card” Law, Use CoA As Legal Documents
Enforcement actions brought by the Federal Trade Commission against dietary ingredient companies that provide false or misleading certificates of analysis to supplement manufacturers could be an effective mechanism for assuring supply quality, according to Utah Natural Products Alliance Executive Director Loren Israelsen
CAM Guidance Confuses Issue Of FDA Authority, Omits Key Points, Groups Say
Dietary supplement industry trade groups say FDA's draft guidance intended to clarify the agency's regulation of complementary and alternative medicine products in fact confuses the issue further, with one group saying the draft should be withdrawn
Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts
FDA should consider issuing a guidance for probiotics similar to the 2004 industry guidance for botanical drugs, panelists said at a recent Drug Information Association conference